Related Experiment Video
Updated: Jul 5, 2025
10:33
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
2.7K
Ponesimod-Associated Macular Edema: Onset and Resolution.
Hartej Singh1, Kush Patel2, Alexander Port2
1Robert Wood Johnson Medical School, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
Journal of Vitreoretinal Diseases
|January 15, 2024
Summary
Ponesimod, a medication for multiple sclerosis, may cause cystoid macular edema (CME). Stopping ponesimod and using topical treatments effectively resolved CME in a patient, offering a management strategy.
Area of Science:
- Ophthalmology
- Neurology
Background:
- Ponesimod is an oral sphingosine-1-phosphate receptor modulator used for treating relapsing-remitting multiple sclerosis.
- Ocular side effects of sphingosine-1-phosphate receptor modulators are a known concern, necessitating vigilant monitoring.
Observation:
- A 75-year-old woman with multiple sclerosis developed cystoid macular edema (CME) in her left eye nine months after initiating ponesimod therapy.
- The patient had no prior ophthalmic abnormalities before starting ponesimod.
Findings:
- The patient's CME resolved completely after discontinuing ponesimod and initiating treatment with topical corticosteroids and nonsteroidal anti-inflammatory drugs.
- This case highlights a potential association between ponesimod and the development of CME.
Implications:
- This report is the first to describe ponesimod-associated macular edema and its successful management.
- Discontinuation of ponesimod combined with topical ocular therapy appears to be an effective strategy for resolving this adverse event.
